Shares of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL – Get Free Report) have received a consensus rating of “Hold” from the ten analysts that are currently covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, four have issued a hold rating and five have assigned a buy rating to the company. The average 1 year target price among analysts that have issued ratings on the stock in the last year is $6.75.
A number of research firms have commented on ZNTL. Mizuho began coverage on shares of Zentalis Pharmaceuticals in a research note on Friday, July 17th. They issued an “outperform” rating and a $8.00 price target for the company. Weiss Ratings restated a “sell (d-)” rating on shares of Zentalis Pharmaceuticals in a research report on Monday, July 6th. Wall Street Zen downgraded shares of Zentalis Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Saturday, August 8th. Rodman & Renshaw assumed coverage on shares of Zentalis Pharmaceuticals in a research report on Thursday, July 23rd. They issued a “buy” rating and a $11.00 target price for the company. Finally, William Blair initiated coverage on shares of Zentalis Pharmaceuticals in a research report on Wednesday. They issued an “outperform” rating for the company.
View Our Latest Analysis on Zentalis Pharmaceuticals
Zentalis Pharmaceuticals Trading Down 1.0%
Zentalis Pharmaceuticals (NASDAQ:ZNTL – Get Free Report) last posted its quarterly earnings data on Thursday, August 6th. The company reported ($0.59) earnings per share for the quarter, missing the consensus estimate of ($0.49) by ($0.10). As a group, analysts predict that Zentalis Pharmaceuticals will post -2.14 earnings per share for the current year.
Insider Transactions at Zentalis Pharmaceuticals
In other news, major shareholder Group Walters purchased 4,335,000 shares of the company’s stock in a transaction on Friday, August 14th. The stock was purchased at an average price of $3.50 per share, with a total value of $15,172,500.00. Following the completion of the purchase, the insider directly owned 17,844,973 shares in the company, valued at approximately $62,457,405.50. This trade represents a 32.09% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. 3.80% of the stock is currently owned by company insiders.
Hedge Funds Weigh In On Zentalis Pharmaceuticals
Large investors have recently modified their holdings of the company. CTC Alternative Strategies Ltd. purchased a new stake in Zentalis Pharmaceuticals in the first quarter worth approximately $29,000. Spark Investment Management LLC bought a new stake in shares of Zentalis Pharmaceuticals in the 2nd quarter worth approximately $61,000. The Manufacturers Life Insurance Company purchased a new stake in shares of Zentalis Pharmaceuticals in the 2nd quarter valued at $69,000. State of Wyoming purchased a new stake in shares of Zentalis Pharmaceuticals in the 2nd quarter valued at $91,000. Finally, Sivia Capital Partners LLC bought a new position in shares of Zentalis Pharmaceuticals during the 4th quarter valued at $27,000.
Zentalis Pharmaceuticals Company Profile
Zentalis Pharmaceuticals, Inc (NASDAQ: ZNTL) is a clinical-stage biopharmaceutical company focused on discovering and developing small-molecule medicines for the treatment of cancer. The company’s research programs are designed to address biological mechanisms involved in tumor growth, resistance to treatment and disease progression.
Zentalis’ lead product candidate is azenosertib, formerly known as ZN-c3, an oral, selective WEE1 kinase inhibitor. The company is evaluating azenosertib in clinical studies involving solid tumors and hematologic malignancies, including ovarian cancer, uterine serous carcinoma and other cancers.
Featured Stories
- Five stocks we like better than Zentalis Pharmaceuticals
- 3 Luxury Consumer Brands to Watch in a Beaten-Down Sector
- Jackson’s Record Quarter Powers the Bull Case
- Holiday Shopping Is Almost Here—And Target May Be Ready to Win Big
- AI Panic Hit Tech Stocks—But NVIDIA’s Growth Engine Is Intact
Receive News & Ratings for Zentalis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zentalis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
